StockData
Septerna, Inc. logo

Septerna, Inc. (SEPN) stock

SEPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30176% above fair value
$41.67−0.93 (-2.18%)

Close on Nov 16, 2026Market cap $1.95BP/E –Yield –

Septerna r&d expenses

Research and development expenses are spending on new products and technology.

Septerna's R&D Expenses for the twelve months ending Sep 30, 2026 was $133.08M, up 56.5% year over year. For fiscal 2025 it was $97.58M, up 49.4% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$97.58M+49.4%
FY2024Dec 31, 2024$65.34M+81.6%
FY2023Dec 31, 2023$35.98M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$36.56M+50.7%
Q2 FY2026Jun 30, 2026$35.13M+58.3%
Q1 FY2026Mar 31, 2026$29.54M+53.3%
Q4 FY2025Dec 31, 2025$31.86M+64.9%
Q3 FY2025Sep 30, 2025$24.26M+36.1%
Q2 FY2025Jun 30, 2025$22.19M+47.6%
Q1 FY2025Mar 31, 2025$19.27M+46.5%
Q4 FY2024Dec 31, 2024$19.32M+87.1%
Q3 FY2024Sep 30, 2024$17.83M+92.1%
Q2 FY2024Jun 30, 2024$15.04M–
Q1 FY2024Mar 31, 2024$13.15M–
Q4 FY2023Dec 31, 2023$10.33M–
Q3 FY2023Sep 30, 2023$9.28M–

More Septerna figures

See a number that looks wrong?